Drugs / ARO-ENaC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04375514 | Jul 2020 → May 2021 | cystic fibrosis | Arrowhead Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-07-02 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC |
| 2020-04-10 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis arrowheadpharma.com ↗ |
| 2019-10-31 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference arrowheadpharma.com ↗
The data presented today show that ARO-ENaC can accelerate mucociliary clearance in normal sheep and also preserve airway physiology in a sheep disease model of impaired mucociliary clearance. |
| 2018-10-16 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics arrowheadpharma.com ↗
In addition, improved mucociliary clearance was observed in sheep two weeks after inhalation of aerosolized ARO-ENaC Gen 1. |
| 2018-05-21 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International Conference in San Diego, CA. |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-ENaC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375514 ↗ |
| Route | Inhaled | “by inhalation of nebulized solution” NCT04375514 ↗ |